Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

Low Rate of Splenic Involvement in Sporadic Burkitt Lymphoma on PET CT

Tima Davidson, Eldar Priel, Gina Schiby-Brilliant, Stephen Raskin, Bar Chikman, Ohad Benjamini, Elinor Goshen, Simona Ben-Haim, Ophira Salomon and Abraham Avigdor
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 1099;
Tima Davidson
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eldar Priel
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gina Schiby-Brilliant
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Raskin
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bar Chikman
1Assaf Harofeh Medical Center Zerifin Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ohad Benjamini
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elinor Goshen
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simona Ben-Haim
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ophira Salomon
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abraham Avigdor
2Chaim Sheba Medical Center RAMAT-GAN Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1099

Objectives: Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma. Cross-sectional anatomic imaging techniques e.g., CT, US, MRI to detect spleen involvement by lymphoma have known limitations, reducing the accuracy of disease staging. This study evaluated the impact of functional imaging with PET-CT in determining splenic involvement at staging in adult patients with sporadic BL

Methods: Twenty patients with sporadic BL, (17 males, 3 women ) median age 49 years [range 22-78] underwent 18F-FDG PET-CT scans at diagnosis at Sheba Medical Center during 1/2005 - 12/2014.. Location and intensity of FDG uptake in tissues involved with BL were assessed and findings were correlated to CT scans. Splenic volume of each patient was calculated by CT (splenomegaly determined if splenic index exceeded 725 cm3). .

Results: Tissue involvement by BL was characterized by high intensity uptake of FDG with a mean SUV max of 11.4 ± 7.49 (range 4.3-38). According to PET-CT, the frequency of BL involvement in various tissues were as follows: lymph nodes n-13 (65%), intestine n- 8 (40%), intraperitoneal fat and omentum n- 7 (35%), stomach n- 5 (25 %), pleura n- 4 (20%), pancreas n-4 (20%), bone marrow n-3 (15%), adrenal gland n- 1 (5 %), liver n- 1(5 %), and seminal vesicle n- 1 (5%). The mean spleen volume (cm3) was 416.6 ± 275.7 (range 140-1358). None of the 20 patients had either focal or diffuse increased uptake of FDG in the spleen parenchyma. In 2 cases there were highly FDG avid soft tissue masses adjacent to the spleen, both in the context of direct peritoneal disease extension.

Conclusion: PET-CT revealed that highly intense FDG uptake is the hallmark of BL involvement in tissue. The spleen is rarely involved by BL and mostly related to direct extension from adjacent peritoneal mass. We conclude that PET- CT can be used for accurate assessment of staging BL, and in the event of an increased avidity of 18F-FDG in the spleen parenchyma one might reconsider diagnosis of BL. Larger scale clinical studies incorporating PET-CT scans are still needed to confirm our observation. Research Support: none

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Low Rate of Splenic Involvement in Sporadic Burkitt Lymphoma on PET CT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Low Rate of Splenic Involvement in Sporadic Burkitt Lymphoma on PET CT
Tima Davidson, Eldar Priel, Gina Schiby-Brilliant, Stephen Raskin, Bar Chikman, Ohad Benjamini, Elinor Goshen, Simona Ben-Haim, Ophira Salomon, Abraham Avigdor
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 1099;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Low Rate of Splenic Involvement in Sporadic Burkitt Lymphoma on PET CT
Tima Davidson, Eldar Priel, Gina Schiby-Brilliant, Stephen Raskin, Bar Chikman, Ohad Benjamini, Elinor Goshen, Simona Ben-Haim, Ophira Salomon, Abraham Avigdor
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 1099;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Clinical Experience with 18F-fluciclovine (Axumin) in Prostate Cancer Patients with a Rising PSA After Primary Treatment
Show more Oncology, Clinical Diagnosis Track

Leukema/Lymphoma/Myeloma Posters

  • Prognostic analysis on 18F-FDG PET/CT and MYC gene in early chemotherapy with diffuse large B-cell lymphoma
  • The Value of 18F-FDG-PET/CT in Early Detecting Asymptomatic Drug-Induced Pneumonitis in Patients with Lymphoma
  • Evaluation of FDG uptake patterns in POEMS syndrome on 18-FDG PET/CT.
Show more Leukema/Lymphoma/Myeloma Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire